### ü´† Heart Failure: Acute Decompensated Heart Failure and Diuretic Therapy

#### ‚úÖ True Statements
1. In patients with **acute decompensated heart failure (ADHF)** and **volume overload**, the most appropriate **initial dose** of **intravenous loop diuretics** is **twice the usual outpatient oral dosage**.
2. If patients with **acute decompensated heart failure** fail to achieve **adequate diuresis** with a loop diuretic, **adding a thiazide diuretic** such as **metolazone** may be considered.
3. **Dopamine** and other **inotropic agents** have **not been shown** to improve outcomes in patients hospitalized with **acute heart failure**.
4. In patients hospitalized with **acute heart failure**, an adequate **urinary response** to diuretics is defined as a **urine sodium >50‚Äì70 mEq/L** within 2 hours and a **urine output >100 mL/h** over the next 6 hours.
5. Patients with **acute decompensated heart failure and adequate blood pressure** who are already tolerating **valsartan-sacubitril** should **continue this therapy** during hospitalization.
6. In general, **guideline-directed medical therapy** for chronic heart failure should be **maintained** during an episode of **acute decompensation**, unless contraindications arise.
7. In patients with **decompensated heart failure and low cardiac output**, **Œ≤-blockers** may need to be temporarily discontinued but should be **reinitiated once euvolemia is achieved**.

#### üí¨ Extra
1. Guidelines support doubling the home dose of loop diuretics when switching from oral to intravenous administration.
2. Sequential nephron blockade with thiazide diuretics is used when loop diuretics alone are insufficient.
3. The ROSE trial showed no benefit of dopamine or nesiritide for decongestion or renal outcomes.
4. These markers help assess effectiveness of diuresis and guide further diuretic management.
5. Valsartan-sacubitril provides mortality and hospitalization benefits and should not be stopped unless hypotension occurs.
6. Discontinuing heart failure medications can lead to worse outcomes and should be avoided unless absolutely necessary.
7. Œ≤-blockers have negative inotropic effects and may exacerbate symptoms during acute decompensation.

#### üî∑ Tags
#Cardiology #EmergentCare #HeartFailure #LoopDiuretics #Metolazone #ValsartanSacubitril #HospitalCare

#### üìô Reference
Mauro C, Chianese S, Cocchia R, et al. Acute heart failure: diagnostic-therapeutic pathways and preventive strategies‚Äîa real-world clinician's guide. *J Clin Med*. 2023;12. PMID: 36769495 doi:10.3390/jcm12030846

#### üÜî Question ID
CVMCQ24100

#### üïí Last Updated
February 2025

---

#### üìñ Related Text
MKSAP 19: Cardiovascular Medicine ‚Äî Heart Failure, Acute Decompensated Heart Failure

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. Initial management of **acute decompensated heart failure (ADHF)** includes identifying the **cause of decompensation**, evaluating **volume status**, relieving **congestion**, and optimizing **medical therapy**.
2. Common causes of **acute decompensated heart failure** include **fluid overload**, **recurrent ischemia**, **hypertension**, **concomitant illness**, and **nonadherence** to medications or diet.
3. Signs of **volume overload** in acute heart failure include **jugular venous distention**, **crackles**, **ascites**, **orthopnea**, and **peripheral edema**.
4. **Point-of-care ultrasound (POCUS)** can aid in volume assessment, identifying features such as **B lines**, **enlarged inferior vena cava**, and **elevated E/e‚Ä≤ ratio**.
5. In **acute decompensated heart failure**, **loop diuretics** are the principal therapy and can be given as **bolus** or **continuous infusion** with no difference in outcomes.
6. In patients not achieving **adequate diuresis** with loop diuretics, **dose escalation** or the addition of a **thiazide diuretic** may be required.
7. **Low-dose dopamine** provides **no benefit** for improving **diuresis** or **renal outcomes** in acute heart failure.
8. **Intravenous inotropes** may be considered in **ADHF** patients with **low perfusion** or **cardiogenic shock**.
9. In **cardiorenal syndrome**, continued **diuresis** with higher doses may be required even with worsening kidney function.
10. If kidney function worsens **near euvolemia**, diuretics may be **withheld for 1 day** to allow **fluid redistribution**.
11. **Standard heart failure therapies** should be **restarted before discharge** if they were held during hospitalization.
12. **Noninvasive positive pressure ventilation** in **ADHF with respiratory distress** can reduce the need for **intubation** and may lower **mortality**.
13. **Brain natriuretic peptide (BNP)** and **troponin** levels at admission and discharge provide **prognostic information** in **acute heart failure**.
14. **Invasive hemodynamic monitoring** may be useful in patients with **worsening symptoms**, **unclear hemodynamics**, or **worsening renal function**.
15. **Cardiogenic shock** in the setting of **heart failure** is treated with **reperfusion**, **inotropes**, **vasopressors**, and possibly **mechanical circulatory support**.
16. **Mechanical support devices** such as **ventricular assist devices** and **extracorporeal membrane oxygenation (ECMO)** can stabilize patients who fail medical therapy.
17. Preventing **readmission for heart failure** includes achieving **euvolemia**, **medication reconciliation**, **discharge education**, and **early outpatient follow-up**.
18. **Outpatient pulmonary artery pressure monitoring** with an implantable sensor can reduce **hospitalizations** in **New York Heart Association (NYHA) class III** patients.
19. **Milrinone**, a phosphodiesterase inhibitor, provides **very strong inotropic support** and **mild vasodilation**, making it useful in **cardiogenic shock** with elevated systemic vascular resistance.
20. **Dobutamine**, a Œ≤‚ÇÅ- and Œ≤‚ÇÇ-adrenergic receptor agonist, produces **very strong inotropic effects** and **mild vasodilation at low doses**, but may cause **vasoconstriction at higher doses**.
21. **Sodium nitroprusside** induces **vasodilation via nitric oxide production** with **no inotropic effect**, and is used primarily to **reduce afterload** in heart failure and shock.
22. **Nitroglycerin** causes **primarily venous vasodilation** through **nitric oxide production**, with **no significant inotropic effect**.
23. **Vasopressin**, an arginine vasopressin receptor agonist, has **vasoconstrictive properties** and **no inotropic benefit**, making it useful in **vasodilatory shock states**.
24. **Dopamine** has **dose-dependent effects**: at low to intermediate doses it has **positive inotropy** via Œ≤‚ÇÅ stimulation; at high doses, it causes **vasoconstriction** via Œ±‚ÇÅ stimulation.
25. **Norepinephrine** primarily stimulates **Œ±‚ÇÅ- and Œ±‚ÇÇ-adrenergic receptors** with **lesser Œ≤‚ÇÅ activity**, resulting in **vasoconstriction and mild inotropy**, making it a first-line agent for **cardiogenic shock with hypotension**.
26. The **choice of diuretic therapy** in **acute decompensated heart failure (ADHF)** depends on the patient's **blood pressure**, **setting of care** (e.g., emergency department), and **clinical trajectory**.
27. In patients with **acute heart failure**, intravenous loop diuretics are the **initial treatment of choice** regardless of the clinical trajectory.

#### üí¨ Extra
1. Causes of decompensation may be reversible and should be addressed early.
2. Identifying precipitating factors helps prevent recurrence.
4. POCUS enhances physical exam sensitivity in detecting congestion.
5. The DOSE trial showed similar efficacy for bolus and continuous IV diuretics.
8. Inotropes should be reserved for patients with hypotension and hypoperfusion.
9. Worsening kidney function does not always warrant stopping diuretics if congestion persists.
13. Persistently elevated BNP or troponin levels are associated with poor outcomes.
17. Structured discharge processes reduce readmissions and mortality.
18. Remote hemodynamic monitoring helps guide early interventions and prevent volume overload.
19. Milrinone is especially helpful in patients with **pulmonary hypertension** or **right ventricular failure**, but may cause **hypotension**.
20. Dobutamine‚Äôs Œ≤‚ÇÇ effects contribute to vasodilation, but Œ±-receptor effects at higher doses may increase **afterload**.
21. Nitroprusside must be used cautiously due to the risk of **cyanide toxicity**, especially in renal dysfunction or prolonged use.
22. Nitroglycerin is commonly used to **relieve pulmonary congestion** in ADHF due to its **venodilation** and preload reduction.
23. Vasopressin can be used as an adjunct to catecholamines in **vasodilatory or distributive shock**, such as **septic shock**.
24. Dopamine‚Äôs profile varies by dose: <5 mcg/kg/min (renal vasodilation), 5‚Äì10 mcg/kg/min (inotropy), >10 mcg/kg/min (vasoconstriction).
25. Norepinephrine is preferred over dopamine for **hemodynamic support** due to a **lower risk of arrhythmias**.
26. The **clinical trajectory** figure categorizes patients by **volume status and perfusion** to guide escalation of diuretic strategies or initiation of vasodilators/inotropes.
27. Patients presenting with **hypotension** in ADHF may require **inotropes** or **mechanical support** instead of aggressive diuresis.

#### üî∑ Tags
#Cardiology #HeartFailure #AcuteDecompensation #LoopDiuretics #ThiazideDiuretics #POCUS #CardiorenalSyndrome #MechanicalSupport #BNP #CardiogenicShock #ReadmissionPrevention #Inotropes #Vasodilators #Milrinone #Dobutamine #Vasopressin #Norepinephrine #Dopamine #Nitroprusside #Nitroglycerin #DiureticTherapy #ClinicalTrajectory

---

### üñºÔ∏è Supplemental Figures, Tables, and Videos

#### üìπ Jugular Venous Distention (Video)

<figure>
  <video controls src="Jugular Venous Distention.mp4"></video>
  <figcaption>
    This neck examination shows <strong>jugular venous distention</strong>, reflecting increased <strong>right atrial pressure</strong>, most likely caused by <strong>left-sided heart failure</strong>.
  </figcaption>
</figure>

---

#### üóæ Intravenous Vasoactive Medications Table

<table>
  <caption><strong>Intravenous Vasoactive Medications Used for Treatment of Cardiogenic Shock</strong></caption>
  <thead>
    <tr>
      <th>Medication</th>
      <th>Mechanism</th>
      <th>Inotropy</th>
      <th>Vasodilation</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Milrinone</td>
      <td>Phosphodiesterase inhibition</td>
      <td>++</td>
      <td>+</td>
    </tr>
    <tr>
      <td>Dobutamine</td>
      <td>Œ≤<sub>1</sub>-, Œ≤<sub>2</sub>-Receptor agonism</td>
      <td>++</td>
      <td>(+) (at low dose)<br>‚àí (vasoconstriction at high dose)</td>
    </tr>
    <tr>
      <td>Sodium nitroprusside</td>
      <td>Nitric oxide production</td>
      <td>0</td>
      <td>++</td>
    </tr>
    <tr>
      <td>Nitroglycerin</td>
      <td>Nitric oxide production</td>
      <td>0</td>
      <td>++ (mainly venous)</td>
    </tr>
    <tr>
      <td>Vasopressin</td>
      <td>Arginine vasopressin receptor (V receptor) agonism</td>
      <td>‚àí</td>
      <td>‚àí (vasoconstriction)</td>
    </tr>
    <tr>
      <td>Dopamine</td>
      <td>
        Dopaminergic receptor (D receptor) agonism<br>
        Œ≤<sub>1</sub>-Receptor agonism at intermediate dose<br>
        Œ±<sub>1</sub>-Receptor agonism at high dose
      </td>
      <td>+</td>
      <td>‚àí (vasoconstriction at high dose)</td>
    </tr>
    <tr>
      <td>Norepinephrine</td>
      <td>Œ±<sub>1</sub>-, Œ±<sub>2</sub>-Receptor agonism greater than Œ≤<sub>1</sub>-receptor agonism</td>
      <td>+</td>
      <td>‚àí (vasoconstriction)</td>
    </tr>
  </tbody>
</table>

<p><em>Strength of effect: ++ indicates very strong; + indicates strong; (+) indicates weak; 0 indicates neutral; ‚àí indicates opposite effect.</em></p>

---

#### üñºÔ∏è Diuretic Therapy in Different Clinical Trajectories (Figure)

<figure>
  <img src="Diuretic Therapy in Different Clinical Trajectories.svg" alt="Diuretic Therapy Algorithm for ADHF">
  <figcaption>
    Summary of <strong>diuretic strategies</strong> for patients hospitalized with <strong>acute heart failure</strong> based on <strong>blood pressure</strong>, <strong>setting</strong>, and <strong>clinical trajectory</strong>.<br>
    BP = blood pressure; ED = emergency department; IV = intravenous.<br>
    Reprinted from: Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure. <em>J Am Coll Cardiol</em>. 2019;74:1982. PMID: 31526538 doi:10.1016/j.jacc.2019.08.001. ¬©2019, with permission from American College of Cardiology Foundation.
  </figcaption>
</figure>